"\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . "ensayu cl\u00EDnicu"@ast . . . . . . . . "Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3]"@en . "2008-07-01T00:00:00Z"^^ . . "TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer"@en . . "klinisch onderzoek"@nl . . . "NCT00102973" . . . . . "244"^^ . . . . . . . . . . . . . . "2004-12-01T00:00:00Z"^^ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer"@en . . "clinical trial"@en . . "TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer"@en . . . .